Hormone therapy · Off-label SERM

Enclomiphene, oral SERM for secondary hypogonadism and fertility preservation.

Enclomiphene offers something TRT cannot: the possibility of raising testosterone without shutting down the body's own production. For men who want to preserve fertility, avoid injections, or are uncertain about committing to exogenous testosterone long-term, enclomiphene, a selective estrogen receptor modulator (SERM) that stimulates the HPG axis, is a clinically reasonable alternative for appropriate candidates.

Schedule a complimentary consultationTalk to a Provider
Small cream prescription envelope with unbranded cream pill bottle resting on top, on warm-wood desk.

What it is

Enclomiphene is the trans-isomer of clomiphene citrate. Where clomiphene citrate is a mixture of two geometric isomers (zuclomiphene and enclomiphene), enclomiphene as a standalone compound delivers the active SERM activity with less of the estrogenic effects attributed to the cis-isomer.

Clomiphene citrate is FDA-approved for female infertility (ovulation induction). In men, enclomiphene is used off-label to stimulate the hypothalamic-pituitary-gonadal (HPG) axis and raise endogenous testosterone without the reproductive suppression caused by exogenous testosterone. In the United States, enclomiphene as a standalone compound is available only through 503A compounding pharmacies with a valid prescription.

How it works

Estrogen receptor blockade at the HPG axis. Enclomiphene occupies estrogen receptors at the hypothalamus and pituitary, blocking estradiol's normal negative feedback signal. The hypothalamus, no longer receiving the "enough estrogen" signal, increases GnRH (gonadotropin-releasing hormone) pulse frequency.

LH and FSH rise. Increased GnRH drives the pituitary to secrete more LH and FSH. LH is the primary stimulus for Leydig cell testosterone production. FSH supports Sertoli cells and spermatogenesis.

Endogenous testosterone and sperm production preserved. Because the signal comes from the body's own HPG axis (stimulated rather than bypassed), Leydig cells produce more testosterone and spermatogenesis continues. This is the key fertility-preserving distinction versus TRT, which suppresses LH and FSH entirely.

Conditions and use cases

Who enclomiphene is appropriate for.

  • Men with secondary hypogonadism and preserved testicular function.
  • Men who want to maintain fertility and spermatogenesis.
  • Men with milder testosterone deficiency who want to avoid exogenous testosterone indefinitely.
  • Men who prefer an oral protocol over weekly injections.
  • Men transitioning off TRT and seeking to stimulate HPG axis recovery.
  • Not appropriate for primary hypogonadism (Klinefelter, testicular injury), visual disturbances or optic neuropathy history, active malignancy, or men needing rapid high-level testosterone restoration.

Expected timeline

What patients commonly observe.

  1. Week 0 to 2

    HPG signal builds

    LH and FSH rise. Total testosterone begins increasing toward physiologic range.

  2. Week 2 to 4

    Symptomatic onset

    Energy and libido improvements begin to emerge in responders.

  3. Month 1 to 3

    Stabilization

    Stabilization of testosterone in physiologic range. Spermatogenesis maintained.

  4. Month 3 to 6

    Long-term plan

    Provider reassesses dose and continuation. Some patients transition to maintenance dosing or alternate protocols.

Stacks that include this therapy

Enclomiphene appears in this stack.

Investment and access

Care plans, not menus.

Genesis Longevity therapies are dispensed only after a complimentary consultation and Good Faith Exam. Schedule yours to receive a personalized plan tailored to your biology and goals.

Schedule a complimentary consultationRequest a custom plan

Side effects

What patients commonly report.

Hot flashes (estrogen receptor blockade produces vasomotor symptoms similar to those seen in women on SERMs; typically mild and manageable). Mood changes and irritability common in initial weeks. Headache. GI upset (nausea, bloating). Less commonly: visual disturbances (class effect, report immediately) and gynecomastia from estradiol elevation, usually mild at appropriate doses.

Contraindications

Who should not use this therapy.

Show contraindications

Primary hypogonadism with non-functional testes. HPG stimulation will not raise testosterone.

Visual disturbances or history of optic neuropathy. Class-wide SERM precaution.

Active malignancy. SERM activity in some tissue contexts is unclear.

Mood disorders. Mood lability reported with SERM therapy. Caution and monitoring required.

Pairs well with

Therapies that complement this protocol.

Frequently asked

Frequently asked questions about Enclomiphene.

Sources

Citations & references

  1. [1]Fountain of You MD, TRT vs Enclomiphene: how they work and key differences. Source
  2. [2]RexMD, Enclomiphene or TRT. Source
  3. [3]Healthspan, Men's Hormone Health program overview. Source
  4. [4]Concierge MD, TRT vs Enclomiphene detailed comparison. Source
  5. [5]Drip Hydration, Enclomiphene vs TRT. Source

Status & disclosures

FDA status: not FDA-approved for male hypogonadism
Enclomiphene is not FDA-approved for male hypogonadism. It is available via 503A compounding as an off-label treatment for secondary hypogonadism in men.
Off-label SERM use
Use of enclomiphene in men relies on the SERM mechanism applied off-label. Clomiphene citrate is FDA-approved for female ovulation induction.
503A compounded preparation
Enclomiphene as a standalone compound is dispensed by licensed 503A pharmacies under valid prescription.
Provider supervision required
Therapy requires a Good Faith Exam and provider consultation. Visual disturbances should be reported immediately.

Next step

Talk to a Genesis provider about Enclomiphene.

Schedule a consultation. Physician-led, evidence-graded.

Book a ConsultationTalk to a Provider

Or keep reading: See the Male Vitality stack